Expression of CD133 and Notch1 in non-small cell lung cancer and the clinicopathological significance
10.3969/j.issn.1673-4254.2015.02.08
- VernacularTitle:非小细胞肺癌中CD133和Notch1的表达及其临床病理意义
- Author:
Lei ZHOU
1
;
Shiwu WU
;
Lan YU
;
Xiaomeng GONG
;
Wenqing SONG
;
Zenong CHENG
Author Information
1. 蚌埠医学院第一附属医院病理科/蚌埠医学院病理学教研室
- Keywords:
non-small cell lung cancer;
cancer stem cells;
CD133;
Notch1;
vascular endothelial growth factor
- From:
Journal of Southern Medical University
2015;(2):196-201
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the presence of cancer stem cells (CSCs) exist in non-small cell lung cancer (NSCLC) and explore the relationship among the expressions of CD133, Notch1, and vascular endothelial growth factor (VEGF) and their relations with the clinicopathological parameters of the patients. Methods A total of 305 specimens of NSCLC and 80 normal lung tissue specimens were analyzed for CD133, Notch1, and VEGF protein expressions by immunohistochemical staining. Results In NSCLC specimens, the positivity rates of CD133, Notch1, and VEGF were 48.9%, 43.9%, and 45.6%, respectively, significantly higher than those in normal lung tissues (10.0%, 15.0%, and 0%, respectively, P<0.01). The expression levels of CD133, Notch1, and VEGF proteins were significantly correlated with the tumor grades, lymph node metastasis, TNM stages, and postoperative survival time of the patients (P<0.01). A positive correlation was found among the expression levels of CD133, Notch1, and VEGF proteins. Kaplan-Meier survival analysis showed a significantly lower overall mean survival time of the patients positive for CD133, Notch1, and VEGF than that of the negative patients (P<0.001). Cox regression analysis suggested that positive expressions of CD133 and Notch1 were independent prognostic factors of NSCLC (P<0.05). Conclusions CD133, Notch1, and VEGF may play important roles in the occurrence, progression, invasion, and metastasis of NSCLC. CD133 and Notch1 have important values for predicting the prognosis and evaluating disease progression of the patients.
